Overview

This trial is active, not recruiting.

Conditions schizophrenia, schizo-affective disorder
Treatment risperidone implant
Phase phase 2
Sponsor Braeburn Pharmaceuticals
Start date October 2015
End date July 2017
Trial size 50 participants
Trial identifier NCT02658357, BB-PK-103

Summary

The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification pharmacokinetics study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Two, 300 mg Risperidone Implants
risperidone implant
(Experimental)
Three, 300 mg Risperidone Implants
risperidone implant

Primary Outcomes

Measure
Area Under the Curve (AUC) for active moiety, 9-hydroxy-risperidone and risperidone
time frame: 6 months
Cmax for active moiety, 9-hydroxy-risperidone and risperidone
time frame: 6 months

Secondary Outcomes

Measure
Safety and efficacy of a Risperidone Implant as assessed by the Positive and Negative Syndrome Scale (PANSS)
time frame: 12 months

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: 1. Subject (and/or a subject's authorized legal representative) has provided written informed consent 2. Patient meets the following criteria: - Outpatient status - PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20% change from screening, the patients cannot participate in the study. - A score of ≤ 3 on the following PANSS items: - Conceptual disorganization - Suspiciousness - Hallucinatory behavior - Unusual thought content 3. Subject is male or female between 18 to 60 years of age 4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria Exclusion Criteria: 1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator 2. Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide 3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening. 4. Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or renal function (eGFR<50 mL/min) 5. Previously defined hypersensitivity to Risperidone 6. History of neuromalignant syndrome (NMS) 7. Electroconvulsive therapy within 6 months of admission 8. Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6

Additional Information

Official title Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Description The study will be a 6-month, open-label, study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants. Subjects who are diagnosed with schizophrenia or schizoaffective disorder according to DSM-V and are stable on a daily 4 mg oral dose of Risperidone for at least 8 weeks will be recruited into the study. Subjects stable on a 4 mg oral dose of Risperidone will be implanted with two or three, 300 mg, Risperidone Implants. All implants will be placed in the inner aspect of the upper arm. Plasma concentrations of Risperidone and the active moiety will be measured prior to placement of the Risperidone Implants, throughout the implantation period, and after re-converting to oral Risperidone following the removal of the Risperidone Implants.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Braeburn Pharmaceuticals.